07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Affibody, Swedish Orphan Biovitrum deal

Swedish Orphan exercised its option under a 2012 deal to develop treatments for inflammatory diseases where IL-1 is implicated. Sobi said it will have exclusive licensing rights within the interleukin field. The companies declined to...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Affibody, Biotest deal

The companies will combine Affibody’s Albumod technology, which improves the circulatory half-life of biopharmaceuticals, with undisclosed Biotest compounds. Following the research phase, Biotest will have the option to exclusively license the technology to develop and...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Affibody, Nordic Nanovector deal

The companies partnered to discover and develop radioimmunotherapies to treat multiple myeloma. Under the three-year deal, the partners will combine Affibody’s platforms with Nordic Nanovector’s radioimmunotherapy technology. The partners have been awarded about EUR1 million...
17:36 , Dec 18, 2014 |  BC Innovations  |  Distillery Techniques

Techniques: Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent, binding to neonatal Fc receptor

Drug platforms TECHNOLOGY: Drug platforms Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives. Binding to Fc receptors improves the half-life of biopharmaceuticals. Phage display and ELISA...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Affibody, Algeta deal

Algeta disclosed in its 2012 earnings that in February it deemed platelet derived growth factor receptor B ( PDGFRB ; PDGFR1 ; CD140B ) an unsuitable target for alpha-pharmaceutical development and terminated the target from...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Affibody, Swedish Orphan Biovitrum deal

The companies partnered to discover and develop up to five treatments for autoimmune and inflammatory diseases where IL-1 is implicated. Swedish Orphan has a two-year option to license programs developed under the deal. Affibody will...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Affibody, General Electric deal

Affibody partnered with General Electric's GE Healthcare unit to develop a PET imaging agent for breast and gastric cancer that targets epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu). The...
00:28 , Jun 8, 2012 |  BC Extra  |  Company News

Affibody, GE in deal for HER2-targeted PET imaging agent

Affibody AB (Stockholm, Sweden) partnered with GE Healthcare to develop a PET imaging agent for breast and gastric cancer that targets epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu). The...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Affibody, Algeta deal

Algeta received exclusive, worldwide rights to two Affibody carrier molecules targeting epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu) and platelet derived growth factor receptor B ( PDGFRB ; PDGFR1...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Algeta management update

Algeta ASA (OSE:ALGETA), Oslo, Norway   Business: Cancer   Hired: Lars Abrahmsen as SVP of protein therapeutics, formerly CSO of Affibody AB  ...